Baystate Wealth Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Baystate Wealth Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$109	Hold	200	–	–	﹤0.01%	1289
2023 Q3	$120	Hold	200	–	–	﹤0.01%	998
2023 Q2	$260	Hold	200	–	–	﹤0.01%	999
2023 Q1	$352	Hold	200	–	–	﹤0.01%	988
2022 Q4	$1K	Hold	200	–	–	﹤0.01%	904
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	849
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	869
2022 Q1	$1K	Hold	200	–	–	﹤0.01%	854
2021 Q4	$2K	Hold	200	–	–	﹤0.01%	777
2021 Q3	$2K	Hold	200	–	–	﹤0.01%	701
2021 Q2	$2K	Hold	200	–	–	﹤0.01%	672
2021 Q1	$3K	Hold	200	–	–	﹤0.01%	571
2020 Q4	$3K	Hold	200	–	–	﹤0.01%	544
2020 Q3	$2K	Hold	200	–	–	﹤0.01%	550
2020 Q2	$2K	Hold	200	–	–	﹤0.01%	562
2020 Q1	$1K	Buy	+200	New	+$1.48K	﹤0.01%	571

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Baystate Wealth Management's SGMO Position: Q4 2023 in Review

Baystate Wealth Management held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q4 2023 at 200 shares worth $109. The position accounts for ﹤0.01% of the portfolio, ranked #1289.

Baystate Wealth Management first reported a position in SGMO in Q1 2020 and has held it in 16 quarters since. The position peaked at $3K in Q1 2021. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

Baystate Wealth Management held 200 shares of SANGAMO THERAPEUTICS INC worth $109 as of Q4 2023.
Baystate Wealth Management left its SANGAMO THERAPEUTICS INC share count unchanged in Q4 2023.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1289 holding.
Baystate Wealth Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2020 and has held it in 16 quarters since.
Baystate Wealth Management's SANGAMO THERAPEUTICS INC position peaked at $3K in Q1 2021.
130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.